Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent or Metastatic Olfactory Neuroblastoma
NCT07100704Phase 2Recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in olfactory neuroblastoma (ONB), sponsored by National Cancer Center Hospital East. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
olfactory neuroblastoma (ONB)
Beyond the preview
Go deeper on NCT07100704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100704.